Science 37 Holdings, Inc (SNCE): Price and Financial Metrics
GET POWR RATINGS... FREE!
SNCE Price/Volume Stats
| Current price | $0.27 | 52-week high | $4.31 |
| Prev. close | $0.28 | 52-week low | $0.19 |
| Day low | $0.27 | Volume | 85,300 |
| Day high | $0.28 | Avg. volume | 651,809 |
| 50-day MA | $0.30 | Dividend yield | N/A |
| 200-day MA | $0.80 | Market Cap | 31.74M |
SNCE Stock Price Chart Interactive Chart >
SNCE POWR Grades
- Sentiment is the dimension where SNCE ranks best; there it ranks ahead of 95.41% of US stocks.
- SNCE's strongest trending metric is Sentiment; it's been moving up over the last 76 days.
- SNCE's current lowest rank is in the Quality metric (where it is better than 1.88% of US stocks).
SNCE Stock Summary
- The ratio of debt to operating expenses for SCIENCE 37 HOLDINGS INC is higher than it is for about merely 4.09% of US stocks.
- With a year-over-year growth in debt of -52.81%, SCIENCE 37 HOLDINGS INC's debt growth rate surpasses just 5.44% of about US stocks.
- The volatility of SCIENCE 37 HOLDINGS INC's share price is greater than that of 96.66% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to SCIENCE 37 HOLDINGS INC are BMTX, GAME, MNTK, CUEN, and COOK.
- To dig deeper into the stock's financial statements, go to SNCE's page on browse-edgar?action=getcompany&CIK=0001819113.
SNCE Valuation Summary
- SNCE's price/earnings ratio is -0.3; this is 101.13% lower than that of the median Technology stock.
- SNCE's price/earnings ratio has moved up 4.8 over the prior 30 months.
Below are key valuation metrics over time for SNCE.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SNCE | 2023-05-22 | 0.5 | 0.4 | -0.3 | 0.4 |
| SNCE | 2023-05-19 | 0.5 | 0.5 | -0.3 | 0.4 |
| SNCE | 2023-05-18 | 0.5 | 0.4 | -0.3 | 0.4 |
| SNCE | 2023-05-17 | 0.5 | 0.4 | -0.3 | 0.4 |
| SNCE | 2023-05-16 | 0.5 | 0.4 | -0.3 | 0.4 |
| SNCE | 2023-05-15 | 0.4 | 0.4 | -0.2 | 0.4 |
Science 37 Holdings, Inc (SNCE) Company Bio
Science 37 Holdings, Inc. engages in enabling universal access for clinical research to accelerate the development of treatments for patients and providers. The company develops decentralized clinical trials (DCT) technology platform that enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, as well as sponsors?to power workflows, centralize evidence generation, and harmonize data. It also offers Science 37 Metasite that provides networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating decentralized clinical trials. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, medical device, and biotech companies. The company was formerly known as Science 37, Inc. and changed its name to Science 37 Holdings, Inc. in October 2021. Science 37 Holdings, Inc. was founded in 2014 and is based in Culver City, California.
Latest SNCE News From Around the Web
Below are the latest news stories about SCIENCE 37 HOLDINGS INC that investors may wish to consider to help them evaluate SNCE as an investment opportunity.
Science 37 Wins 2023 MedTech Breakthrough Award for "Best Overall Clinical Trial Platform"Science 37's unified platform that powers the Metasite receives award for outstanding digital health and technology innovationRESEARCH TRIANGLE PARK, N.C., May 18, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™, has been named the winner of the prestigious "Best Overall Clinical Trial Platform" award in the 7th annual MedTech Breakthrough Awards program. Science 37 was chosen by MedTech Breakthrough, an autonomous market intell |
Science 37 Reports First Quarter 2023 Financial ResultsRESEARCH TRIANGLE PARK, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”), the industry-leading Metasite™, today reported its financial results for the quarter ended March 31, 2023. “First quarter results reflected continued progress with our key strategic initiatives,” stated David Coman, Chief Executive Officer of Science 37. “Our recent actions to reduce our cost structure and increase focus on our unique Metasite solution position us well to driv |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time for another dive into the biggest pre-market stock movers traders need to know about as we cover the winners and losers for Friday! |
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., May 05, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a mate |
Science 37 Joins Partnership in Support of White House CancerX and Cancer MoonshotStrategic partnership will leverage Science 37’s leadership in remote and hybrid clinical research to enable expansive clinical trial access for oncology patientsRESEARCH TRIANGLE PARK, N.C., May 02, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading MetasiteTM, today announced its partnership with the Digital Medicine Society (DiMe) in support of the CancerX inaugural project. Answering the call of the White House, Science 37 will join DiMe and Moffitt Cance |
SNCE Price Returns
| 1-mo | -4.90% |
| 3-mo | -18.18% |
| 6-mo | -54.71% |
| 1-year | -92.66% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -34.97% |
| 2022 | -96.67% |
| 2021 | 16.87% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...